Aptose Biosciences Inc.

Precision Oncology for Therapies of Tomorrow

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address the unmet clinical need in chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other hematologic malignancies.

Who We Are View Our Clinical Trials

Broad Applicability Across the Hematology Spectrum

Our drug candidates have been designed to provide safe single agent efficacy in multiple adjacent indications, as well as enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

View Product Pipeline

CG-806: Mutation-Agnostic Agent For B-cell Tumors

CG-806 is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies.

View Candidate

CG-806: Mutation-Agnostic Agent For Myeloid Tumors

CG-806 potently inhibits wildtype and all mutant forms of FLT3 which are an oncogenic drivers in AML and MDS, as well as other oncogenic rescue pathways operative in myeloid malignancies.

View Candidate

APTO-253: MYC Inhibitor For Myeloid Tumors

APTO-253 is the first clinical small molecule that directly and selectively targets the MYC oncogene and inhibits the production of MYC mRNA and protein, leading to cell cycle arrest and apoptosis of tumor cells.

View Candidate

Our Clinical Trials in Hematologic Malignancies

Currently, we have three ongoing clinical trials with our investigational drug candidates:

CG-806: Phase 1a/b

CG-806 is in a Phase 1a/b clinical trial for the treatment of patients with B-cell malignancies, including CLL and NHL, who have failed or are intolerant to the standard treatments available.